Results 231 to 240 of about 53,202 (260)

Addressing Confounders in GLP‐1RA Effects on ALD Outcomes

Liver International
Chi‐Kuei Hsu, Chia‐Chih Kuo, Chih‐Cheng Lai   +2 more
openaire   +2 more sources

Bariatrische Operation versus GLP-1RA

Diabetologie und Stoffwechsel
openaire   +1 more source

GLP-1RA, SGLT2i und Amputationsrisiko

Diabetologie und Stoffwechsel
openaire   +1 more source

Empagliflozin/Finerenon plus GLP-1RA

Diabetologie und Stoffwechsel
openaire   +1 more source

GLP-1RA-related erectile dysfunction

Reactions Weekly
openaire   +1 more source

GLP-1RAs may cause intolerable gastrointestinal AEs

Reactions Weekly, 2023
openaire   +1 more source

Impact of GLP-1RA on the Risk of Adverse Liver Outcomes Among Patients With Alcohol-Associated Liver Disease and Type 2 Diabetes

Liver International
Khalid Mumtaz, Selamawit Woldesenbet
exaly  

Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population

Advances in Therapy, 2017
Hiep Nguyen
exaly  

Walking Further with GLP-1RAs: Lessons from the STRIDE Trial

The International Journal of Lower Extremity Wounds
Dimitrios Pantazopoulos, Stella Papachristou, Prashanth R J Vas, Nikolaos Papanas   +3 more
openaire   +2 more sources

Sociodemographic disparities in GLP-1RA and SGLT2i use among US adults with type 2 diabetes: NHANES 2005-March 2020

Current Medical Research and Opinion
Benjamin G Mittman
exaly